Compare TOMZ & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOMZ | HOTH |
|---|---|---|
| Founded | 1979 | 2017 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 11.7M |
| IPO Year | 2009 | 2018 |
| Metric | TOMZ | HOTH |
|---|---|---|
| Price | $0.76 | $0.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 697.8K | 299.9K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.64 | ★ 29.69 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,635,927.00 | N/A |
| Revenue This Year | $48.56 | N/A |
| Revenue Next Year | $121.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $0.49 |
| 52 Week High | $1.20 | $2.12 |
| Indicator | TOMZ | HOTH |
|---|---|---|
| Relative Strength Index (RSI) | 55.73 | 31.88 |
| Support Level | $0.73 | $0.49 |
| Resistance Level | $0.81 | $0.80 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 58.58 | 15.87 |
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. The product portfolio of the company includes The SteraPak, The Surface Unit, SteraMist Transport, The NV+, The Environment System, and others.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.